Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
Metrics: PDF 897 views | HTML 1591 views | ?
Anjali V. Sheahan1, Andrew V. Biankin2, Christopher R. Parish3 and Levon M. Khachigian4
1Department of Pathology, Dana-Farber Cancer Institute, Boston 02115, MA, United States of America
2Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow G61 1QH, Scotland, United Kingdom
3Cancer and Vascular Biology, ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra ACT 2601, Australia
4Vascular Biology and Translational Research, School of Medical Sciences, University of New South Wales, Sydney NSW 2052, Australia
Levon M. Khachigian, email: L.Khachigian@unsw.edu.au
Keywords: pancreatic cancer; bibliometric analysis; clinical trials
Received: September 14, 2017 Accepted: March 12, 2018 Published: April 20, 2018
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach – combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.